Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company's offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company has a collaboration with Genovis AB to develop and market biopharmaceutical characterization workflows based on the its BioAccord LC-MS System, Andrew+ pipetting robot and Genovis SmartEnzymes. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.
IPO Year: 1995
Exchange: NYSE
Website: waters.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/31/2025 | $460.00 | Sector Weight → Overweight | KeyBanc Capital Markets |
| 3/26/2025 | $396.00 → $407.00 | Neutral → Outperform | Robert W. Baird |
| 2/13/2025 | $450.00 | Sector Perform → Sector Outperform | Scotiabank |
| 2/10/2025 | $360.00 → $415.00 | Underweight → Equal Weight | Barclays |
| 1/10/2025 | $430.00 | Mkt Perform → Outperform | Bernstein |
| 12/23/2024 | Sector Perform | Scotiabank | |
| 10/8/2024 | $355.00 → $415.00 | Hold → Buy | Jefferies |
| 8/28/2024 | $380.00 | Overweight | Wells Fargo |
| 8/1/2024 | $325.00 → $375.00 | Market Perform → Outperform | Leerink Partners |
| 6/3/2024 | $320.00 | Hold | Jefferies |
MILFORD, Mass., May 16, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D., Waters President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4th, 2025, at 8:45AM Eastern Time. A live webcast of the event will be available on the 'Events & Presentations' section of Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will be available for 90 days. About Waters Corporation Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences f
News Summary Saves up to six months on compliant software validation in biopharmaceutical quality control.1Reduces analysis time for biotherapeutic peptides and proteins by 20%.2Enhances quality control by providing absolute molecular weight of biologics and avoiding common errors encountered with other techniques.3MILFORD, Mass., May 6, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced that its Empower™ Software now supports biologics data acquisition and quality control (QC) analysis from Multi-Angle Light Scattering (MALS) and differential Refractive Index (RI) instruments in its Wyatt Technology™ Portfolio. This integration expands the scope of critical quality attribut
Highlights Strong start to the year as first quarter 2025 sales of $662 million landed at the high-end of guidance range; grew 4% as reported and 7% in constant currencyResults led by instrument growth of 11% in constant currency, driven by strong momentum in Pharma and Industrial end marketsEarnings landed at the high-end of guidance range with GAAP EPS of $2.03 and non-GAAP EPS of $2.25Raising full-year constant currency sales growth guidance to +5.0% to +7.0%, given first quarter strengthRaising full-year non-GAAP EPS guidance to the range of $12.75 to $13.05, net of tariff impact, operational actions, and improvement in FXFirst Quarter 2025 MILFORD, Mass., May 6, 2025 /PRNewswire/ -- Wat
STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to
MILFORD, Mass., April 8, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q1 2025 financial results conference call on Tuesday, May 6th, 2025 at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least June 3rd, 2025, at midnight Eastern Time. About Waters Corporation Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences for over 65 years. Our Company helps ensure the efficacy of medicines, the safety of food
News Summary Boosts out-of-the-box sensitivity by up to 80 times with MaxPeakTM Premier columns.1Delivers over threefold improvements in day-to-day reproducibility2 and decreases carryover by up to two orders of magnitude.3Reduces common user errors by up to 40%.4MILFORD, Mass., April 1, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the expansion of the Alliance™ iS Bio HPLC product line with integrated photodiode array (PDA) detection, advancing the capabilities of the next-generation intelligent HPLC platform designed for development and Quality Control (QC) laboratories.
MILFORD, Mass., March 7, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra Ph.D., Waters President and Chief Executive Officer, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Tuesday, March 11th, 2025 at 10:00AM Eastern Time. A live webcast of the event will be available on the 'Events & Presentations' section of Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will be available for 90 days. About Waters Corporation Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sci
Highlights Fourth Quarter 2024 Sales of $873 million exceeded high-end of guidance range, grew 6% as reported and 8% in constant currencyInstruments grew 8% and recurring revenue grew 9% in constant currency, as growth accelerated across all three reported regionsPharma grew 10% in constant currency, reflecting stronger-than-expected year-end spending dynamics and broad-based growth across the Americas, Europe, and AsiaGAAP EPS of $3.88; non-GAAP EPS of $4.10 grew 13% as strong operational performance and better-than-expected sales volume offset foreign exchange headwinds Full-Year 2024 Sales exceeded guidance at $2,958 million, flat as reported and in organic constant currencyGAAP operating
News Summary: Offers increased versatility and data-driven insights with 43% greater motor stroke range (100 mm),1 expanding testing to more materials across diverse industries.Improved dynamic performance completes fatigue testing up to 30% faster than the competition,2 increasing the speed of product development and validation.Designed to simplify testing workflows, with automated controls and fewer process steps to help reduce operator errors and enable safer, more confident testing.ANAHEIM, Calif., and MILFORD, Mass., Feb. 4, 2025 /PRNewswire/ – MD&M West – Waters Corporat
News Summary: New and proprietary product enabling laboratories to analyze atmosphere-sensitive materials used to develop batteries, advanced polymers, and medicines in a standard laboratory benchtop-installed thermogravimetric analyzer (TGA).Reduces the cost and footprint of the TGA system by up to 50%i by helping eliminate the need for environment-controlled housing, or glovebox.Enables laboratories to increase throughput without sacrificing data quality and reliability.MILFORD, Mass., Jan. 22, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the launch of TGA Smart-Seal™ Pans from its TA Instruments Division. The innovative, self-opening sample container is designed to e
4 - WATERS CORP /DE/ (0001000697) (Issuer)
SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)
SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)
SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)
SC 13G - WATERS CORP /DE/ (0001000697) (Subject)
SC 13G - WATERS CORP /DE/ (0001000697) (Subject)
SC 13G - WATERS CORP /DE/ (0001000697) (Subject)
SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)
SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)
SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)
SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)
4 - WATERS CORP /DE/ (0001000697) (Issuer)
4 - WATERS CORP /DE/ (0001000697) (Issuer)
4 - WATERS CORP /DE/ (0001000697) (Issuer)
4 - WATERS CORP /DE/ (0001000697) (Issuer)
4 - WATERS CORP /DE/ (0001000697) (Issuer)
4 - WATERS CORP /DE/ (0001000697) (Issuer)
4 - WATERS CORP /DE/ (0001000697) (Issuer)
4 - WATERS CORP /DE/ (0001000697) (Issuer)
4 - WATERS CORP /DE/ (0001000697) (Issuer)
4 - WATERS CORP /DE/ (0001000697) (Issuer)
Highlights Strong start to the year as first quarter 2025 sales of $662 million landed at the high-end of guidance range; grew 4% as reported and 7% in constant currencyResults led by instrument growth of 11% in constant currency, driven by strong momentum in Pharma and Industrial end marketsEarnings landed at the high-end of guidance range with GAAP EPS of $2.03 and non-GAAP EPS of $2.25Raising full-year constant currency sales growth guidance to +5.0% to +7.0%, given first quarter strengthRaising full-year non-GAAP EPS guidance to the range of $12.75 to $13.05, net of tariff impact, operational actions, and improvement in FXFirst Quarter 2025 MILFORD, Mass., May 6, 2025 /PRNewswire/ -- Wat
STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to
MILFORD, Mass., April 8, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q1 2025 financial results conference call on Tuesday, May 6th, 2025 at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least June 3rd, 2025, at midnight Eastern Time. About Waters Corporation Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences for over 65 years. Our Company helps ensure the efficacy of medicines, the safety of food
Highlights Fourth Quarter 2024 Sales of $873 million exceeded high-end of guidance range, grew 6% as reported and 8% in constant currencyInstruments grew 8% and recurring revenue grew 9% in constant currency, as growth accelerated across all three reported regionsPharma grew 10% in constant currency, reflecting stronger-than-expected year-end spending dynamics and broad-based growth across the Americas, Europe, and AsiaGAAP EPS of $3.88; non-GAAP EPS of $4.10 grew 13% as strong operational performance and better-than-expected sales volume offset foreign exchange headwinds Full-Year 2024 Sales exceeded guidance at $2,958 million, flat as reported and in organic constant currencyGAAP operating
MILFORD, Mass., Jan. 17, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q4 2024 financial results conference call live on Wednesday, February 12th, 2025 at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least March 12th, 2025, at midnight Eastern Time. About Waters Corporation Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, food, and environmental sciences for more than 65 years.
Highlights Sales of $740 million exceeded guidance, grew 4% as reported and 4% in constant currencyInstruments returned to growth; recurring revenue grew high single-digits in constant currencyAll reported regions returned to growth in the quarter; sales grew across all end markets, led by Pharma & IndustrialGAAP EPS of $2.71 and non-GAAP EPS of $2.93 significantly exceeded guidance, led by strong operational performance and better-than-expected market conditionsRaised full-year sales and EPS guidance, with 5% to 7% constant currency growth expected in the fourth quarterThird Quarter 2024 MILFORD, Mass., Nov. 1, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced its financial
MILFORD, Mass., Oct. 7, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q3 2024 financial results conference call live on Friday, November 1st, 2024 at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least November 29th, 2024, at midnight Eastern Time. About Waters Corporation Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, food, and environmental sciences for more than 65 years. W
Highlights Sales of $709 million exceeded guidance on a reported basis, declined 4% as reported and 4% in organic constant currencyGAAP EPS of $2.40; earnings exceeded guidance with non-GAAP EPS of $2.63, led by strong operational performanceBeat driven by better-than-expected performance in China, as well as higher-than-expected M&A contribution to overall sales from WyattEx-China organic constant currency sales growth as expected across Pharma, Industrial, and Academic & Government end marketsFull-year outlook reflects the potential for a more gradual market improvement in the second half of the year than previously anticipatedSecond Quarter 2024 MILFORD, Mass., July 31, 2024 /PRNewswire/
MILFORD, Mass., July 2, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q2 2024 financial results conference call live on Wednesday, July 31st, 2024 at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least August 28th, 2024, at midnight Eastern Time. About Waters Corporation Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, food, and environmental sciences for more than 65 years. Wit
Highlights Sales of $637 million at the high-end of guidance, declined 7% as reported and 9% in organic constant currencyGAAP EPS of $1.72; earnings well above guidance, with non-GAAP EPS of $2.21Operational excellence drove gross margin expansion of 40 basis points and adjusted operating margin expansion of 20 basis pointsStrong operating cash flow generation at $263 million; free cash flow of $234 million was 37% of sales Full-year guidance maintained at -0.5% to +1.5% organic constant currency sales growth and non-GAAP EPS of $11.75 to $12.05First Quarter 2024 MILFORD, Mass., May 7, 2024 /PRNewswire/ -- Waters Corporation (NYSE: WAT) today announced its financial results for the first qua
MILFORD, Mass., Aug. 14, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the appointment of Heather Knight to its Board of Directors effective August 14, 2024. Ms. Knight currently serves as Executive Vice President and Group President, Medical Products and Therapies at Baxter International. Heather is an accomplished leader who brings decades of experience across the pharma and medical device industries."Heather is an accomplished leader who brings decades of experience across the pharmaceutical and medical device industries, with a proven track record for
Waters™ Corporation (NYSE:WAT) today announced the appointment of Richard Fearon to its Board of Directors, effective March 27, 2023. Mr. Fearon is the former Vice Chairman and Chief Financial and Planning Officer of Eaton Corporation, a multinational power management company. "Rick's expertise is at the intersection of financial excellence, strategic development and transformation, which are the key pillars of Waters' growth plan. We are confident that Rick's unique skillset will complement our Board well and we look forward to benefiting from his insights as we continue to drive value for shareholders," said Dr. Flemming Ornskov, Chairman of the Board. Dr. Udit Batra, CEO and President,
Waters Corporation (NYSE:WAT) today announced the appointment of Dan Brennan and Mark Vergnano, to its Board of Directors, effective November 23, 2022. Mr. Brennan currently serves as Executive Vice President and Chief Financial Officer of Boston Scientific Corporation, a global medical device company, and Mr. Vergnano is the former Chairman, President and Chief Executive Officer of The Chemours Company, a chemistry company. "Dan and Mark are outstanding leaders whose decades of experience in the medical device and chemistry industries will add tremendous value as Waters continues to execute its exciting growth strategy," said Dr. Flemming Ornskov, Chairman of the Board. "These appointment
Dr. Michael J. Berendt to Retire from Waters Board Waters Corporation (NYSE:WAT) today announced the appointment of John M. Ballbach to its Board of Directors, effective October 5, 2021. Mr. Ballbach currently serves on the Board of RPM International, Inc., a leader in specialty coatings, sealants, building materials and related services. Waters also announced the retirement of Dr. Michael J. Berendt from its Board of Directors, effective October 5, 2021. Dr. Berendt joined the Waters Board in 1998 and has served on both the company's Audit and Science & Technology committees during his tenure as director. "Our sincere thanks and gratitude on behalf of my colleagues to Mike, for his serv
Waters Corporation (NYSE:WAT) today announced the appointment of Wei Jiang to its Board of Directors, effective July 14, 2021. Mr. Jiang currently serves as Executive Vice President and President, Bayer Pharmaceuticals Region China & APAC and President, Bayer Group Greater China. Dr. Flemming Ornskov, Chairman of the Board, said, "We are excited to welcome Wei to the Board and know that we will benefit from his operating experience and transformation expertise. Wei has an outstanding record of driving results in regions that represent key growth opportunities for Waters, including China and other Asia-Pacific markets. We believe he is a valuable addition to the Board at this pivotal time f
MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) today announced that Dr. Pearl S. Huang, President and CEO of Cygnal Therapeutics and venture partner at Flagship Pioneering, has been appointed as a Director of Waters Corporation, effective January 1, 2021. “We are pleased to welcome Pearl to the Waters Board of Directors,” said Dr. Flemming Ornskov, Chairman of the Board. “Pearl is a distinguished executive with significant scientific expertise in the discovery of biologics, small molecule and nucleic acid-based therapies, as well as a proven track record in drug discovery and the development of clinical trials. We look forward to benefitting from Pearl’s perspecti
MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) today announced that Sherry Buck will step down as Chief Financial Officer, effective December 31, 2020, in order to pursue another opportunity at a privately held company. Upon her departure, Michael F. Silveira, Vice President and Corporate Controller of Waters, will assume the role of interim Chief Financial Officer. Ms. Buck will work alongside Mr. Silveira in order to facilitate a smooth transition. Waters has been actively working with a leading search firm to identify a permanent CFO, and the process is advancing well with several strong internal and external candidates. “On behalf of the Board and management,
10-Q - WATERS CORP /DE/ (0001000697) (Filer)
8-K - WATERS CORP /DE/ (0001000697) (Filer)
DEFA14A - WATERS CORP /DE/ (0001000697) (Filer)
DEF 14A - WATERS CORP /DE/ (0001000697) (Filer)
10-K - WATERS CORP /DE/ (0001000697) (Filer)
8-K - WATERS CORP /DE/ (0001000697) (Filer)
8-K - WATERS CORP /DE/ (0001000697) (Filer)
8-K/A - WATERS CORP /DE/ (0001000697) (Filer)
10-Q - WATERS CORP /DE/ (0001000697) (Filer)
8-K - WATERS CORP /DE/ (0001000697) (Filer)
KeyBanc Capital Markets upgraded Waters from Sector Weight to Overweight and set a new price target of $460.00
Robert W. Baird upgraded Waters from Neutral to Outperform and set a new price target of $407.00 from $396.00 previously
Scotiabank upgraded Waters from Sector Perform to Sector Outperform and set a new price target of $450.00
Barclays upgraded Waters from Underweight to Equal Weight and set a new price target of $415.00 from $360.00 previously
Bernstein upgraded Waters from Mkt Perform to Outperform and set a new price target of $430.00
Scotiabank initiated coverage of Waters with a rating of Sector Perform
Jefferies upgraded Waters from Hold to Buy and set a new price target of $415.00 from $355.00 previously
Wells Fargo initiated coverage of Waters with a rating of Overweight and set a new price target of $380.00
Leerink Partners upgraded Waters from Market Perform to Outperform and set a new price target of $375.00 from $325.00 previously
Jefferies resumed coverage of Waters with a rating of Hold and set a new price target of $320.00